丹参川芎嗪注射液联合尤瑞克林治疗缺血性脑血管病患者的效果

Effects of Danshen ligustrazine injection combined with Urinary kallindinogenase in treatment of patients with ischemic cerebrovascular disease

目的:观察丹参川芎嗪注射液联合尤瑞克林治疗缺血性脑血管病患者的效果。方法:选取2018年8月至2020年8月该院收治的96例缺血性脑血管病患者行前瞻性研究,采用随机数字表法分为观察组与对照组各48例,对照组采用尤瑞克林治疗,观察组在对照组基础上联合丹参川芎嗪注射液治疗。比较两组疗效、治疗前后神经功能缺损[美国国立卫生院卒中量表(NIHSS)]评分、日常生活活动能力(ADL)评分、脂蛋白联脂酶A2(Lp-PLA2)水平、神经烯醇化酶(NSE)水平、血液流变学指标(全血高切黏度、全血低切黏度)水平、血清炎性因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)]水平和不良反应发生率。结果:观察组治疗总有效率为95.83%,高于对照组的77.08%,差异有统计学意义(P<0.05);治疗后,两组NIHSS评分和Lp-PLA2、NSE、全血高切黏度、全血低切黏度、IL-6、CRP水平均低于治疗前,且观察组低于对照组,两组ADL评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为4.17%,与对照组的14.58%比较,差异无统计学意义(P<0.05)。结论:丹参川芎嗪注射液联合尤瑞克林治疗缺血性脑血管病患者可提高治疗总有效率和ADL评分,降低Lp-PLA2、NSE、血液流变学指标和血清炎性因子水平以及NIHSS评分,优于单纯尤瑞克林治疗效果。

Objective:To observe effects of Danshen ligustrazine injection combined with Urinary kallindinogenase in treatment of patients with ischemic cerebrovascular disease.Methods:96 patients with ischemic cerebrovascular disease who were admitted to this hospital from August 2018 to August 2020 were selected for the prospective study,and were divided into observation group and control group by using the random number table method,48 cases in each group.The control group was treated with Urinary kallindinogenase,while the observation group was treated with Danshen ligustrazine injection on the basis of that of the control group.The curative effects,the neurological deficit [national institutes of health stroke scale(NIHSS)] score,the activity of daily living(ADL) score,the lipoprotein lipase A2(Lp-PLA2) level,the neuron-specific enolase(NSE) level,the hemorheological index levels(whole blood high shear viscosity,whole blood low shear viscosity),the serum inflammatory factor levels [interleukin-6(IL-6),C-reactive protein(CRP)] and incidence of adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of the observation group was 95.83%,which was higher than the control group of 77.08%,and the difference was statistically significant(P<0.05).After the treatment,the NIHSS scores and the levels of Lp-PLA2,NSE,whole blood high shear viscosity,whole blood low shear viscosity,IL-6 and CRP in the two groups were lower than those before the treatment,and those of the observation group were lower than those of the control group;the ADL scores in the two groups were lower than those before the treatment,and that of the observation group was higher than that of the control group;and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the observation group was 4.17%,compared with 14.58% in the control group,the difference was not statistically significant(P<0.05).Conclusions:Danshen ligustrazine injection combined with Urinary kallindinogenase in treatment of the patients with ischemic cerebrovascular disease can improve the total effective rate and the ADL score,reduce the levels of Lp-PLA2,NSE,hemorheological indexes,serum inflammatory factors and the NIHSS score.Moreover,it is superior to single Urinary kallindinogenase.